Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

The importance of intestinal residence time of absorption enhancer on drug absorption and implication on formulative considerations

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Affiliation:
      The Hebrew University of Jerusalem, Faculty of Medicine, School of Pharmacy, P.O. Box 12065, Jerusalem 91120, Israel
    • Keywords:
      Absorption
      Absorption enhancement
      Cefazoline
      EDTA
      Ibuprofen
      HPMC
      In vivo analysis
      Sodium decanoate
      Sodium dodecyl sulphate
      Synchronous release
    • Abstract:
      Absorption enhancers are efficient in small body cavities such as the nasal and the rectum. However, in the gastrointestinal tract, where the volume and amount of liquids are large and motility is more profound, dilution may require a constant input of the enhancer with a poorly absorbed drug. Using a perfused rat model, the purpose of the present study was to verify that the synchronized administration of a poorly absorbed drug and an absorption enhancer is required for optimal drug absorption after oral administration. Sodium cefazoline (SCef) was used as the poorly absorbed drug probe and sodium decanoate (SD) as the absorption enhancer. A secondary goal was to examine an erodible matrix formulation as a potential drug carrier for the synchronized release of two probes of different water solubilities. It was found that higher SCef blood levels were obtained after 30 min of co-administration of 50 mM of SD, than after co-administration of 100 mM over 15 min. In both cases SCef blood levels declined within 15–30 min after cessation of enhancer perfusion, a finding which suggests that SCef requires a constant input of SD for its absorption which is more important than the concentration of SD administered. The feasibility of a hydroxypropyl methyl cellulose (HPMC) matrix for the synchronous release of two drug probes with different solubility properties was examined as a potential carrier to maintain constant levels of two drug probes over a predetermined period of time.
    • ISSN:
      0378-5173
    • Accession Number:
      10.1016/S0378-5173(98)00288-9
    • Accession Number:
      S0378517398002889
    • Copyright:
      Copyright @ 1998 Elsevier Science B.V. All rights reserved.
  • Citations
    • ABNT:
      BALUOM, M.; FRIEDMAN, M.; RUBINSTEIN, A. The importance of intestinal residence time of absorption enhancer on drug absorption and implication on formulative considerations. International Journal of Pharmaceutics, [s. l.], v. 176, n. 1, p. 21–30, 1998. DOI 10.1016/S0378-5173(98)00288-9. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edselp&AN=S0378517398002889&custid=s8280428. Acesso em: 2 abr. 2020.
    • AMA:
      Baluom M, Friedman M, Rubinstein A. The importance of intestinal residence time of absorption enhancer on drug absorption and implication on formulative considerations. International Journal of Pharmaceutics. 1998;176(1):21-30. doi:10.1016/S0378-5173(98)00288-9.
    • APA:
      Baluom, M., Friedman, M., & Rubinstein, A. (1998). The importance of intestinal residence time of absorption enhancer on drug absorption and implication on formulative considerations. International Journal of Pharmaceutics, 176(1), 21–30. https://doi.org/10.1016/S0378-5173(98)00288-9
    • Chicago/Turabian: Author-Date:
      Baluom, Muhammad, Michael Friedman, and Abraham Rubinstein. 1998. “The Importance of Intestinal Residence Time of Absorption Enhancer on Drug Absorption and Implication on Formulative Considerations.” International Journal of Pharmaceutics 176 (1): 21–30. doi:10.1016/S0378-5173(98)00288-9.
    • Harvard:
      Baluom, M., Friedman, M. and Rubinstein, A. (1998) ‘The importance of intestinal residence time of absorption enhancer on drug absorption and implication on formulative considerations’, International Journal of Pharmaceutics, 176(1), pp. 21–30. doi: 10.1016/S0378-5173(98)00288-9.
    • Harvard: Australian:
      Baluom, M, Friedman, M & Rubinstein, A 1998, ‘The importance of intestinal residence time of absorption enhancer on drug absorption and implication on formulative considerations’, International Journal of Pharmaceutics, vol. 176, no. 1, pp. 21–30, viewed 2 April 2020, .
    • MLA:
      Baluom, Muhammad, et al. “The Importance of Intestinal Residence Time of Absorption Enhancer on Drug Absorption and Implication on Formulative Considerations.” International Journal of Pharmaceutics, vol. 176, no. 1, Jan. 1998, pp. 21–30. EBSCOhost, doi:10.1016/S0378-5173(98)00288-9.
    • Chicago/Turabian: Humanities:
      Baluom, Muhammad, Michael Friedman, and Abraham Rubinstein. “The Importance of Intestinal Residence Time of Absorption Enhancer on Drug Absorption and Implication on Formulative Considerations.” International Journal of Pharmaceutics 176, no. 1 (January 1, 1998): 21–30. doi:10.1016/S0378-5173(98)00288-9.
    • Vancouver/ICMJE:
      Baluom M, Friedman M, Rubinstein A. The importance of intestinal residence time of absorption enhancer on drug absorption and implication on formulative considerations. International Journal of Pharmaceutics [Internet]. 1998 Jan 1 [cited 2020 Apr 2];176(1):21–30. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edselp&AN=S0378517398002889&custid=s8280428